Amlodipine and fosinopril sodium medical composition and preparation method thereof

A technology of fosinopril sodium and amlodipine is applied in the field of pharmaceutical compositions of amlodipine and fosinopril sodium and their preparation, which can solve the problem of low overall level of blood drug concentration, undisclosed preparation method, increase Drug cost and other issues, to achieve the effect of improving bioavailability, good disintegration performance and dissolution, and stable and long-lasting effect

Active Publication Date: 2012-10-10
HAINAN JINRUI PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the prior art, amlodipine and amlodipine salts (such as amlodipine maleate, amlodipine besylate, amlodipine mesylate, etc.) are almost insoluble in water and are slowly absorbed in the human body. The peak blood concentration is reached in 6-12 hours, and the overall level of blood drug concentration is low, especially the initial blood concentration after administration is very low, and the drug has a very slow onset and slow action; while fosinopril sodium takes 5-7 hours after administration. Reaching the peak concentration of blood concentration, the drug has a slow onset of action, and the pharmaceutical composition with amlodipine or amlodipine salt and fosinopril sodium as active ingredients has a slow onset and slow effect after administration
Chinese patent CN101653440A discloses a composition containing amlodipine salt and pril-like drugs. This patent does not specifically disclose the composition and composition of the excipients in the pharmaceutical composition with amlodipine and fosinopril sodium as active ingredients. In addition, those skilled in the art know that, compared with amlodipine, the solubility and temperature stability of these amlodipine salts are slightly improved, but they are still slightly soluble or even insoluble , is not easily absorbed in the human body. Generally speaking, the time for amlodipine salt to reach the peak blood concentration is still 6-12 hours, and the medicinal composition still takes effect slowly after administration.
[0006] In addition, in order to improve the bioavailability of amlodipine salt, the prior art adopts the method of splitting racemic amlodipine or its salt into levamlodipine or its salt, after administration of levamlodipine or its salt, Although the bioavailability has been improved, the time to reach the peak blood concentration is still 6 to 12 hours, and the onset of action is slow. After administration according to the dose required by the normal human body, the initial blood concentration is very low. Slow onset of action after administration of sodium medicinal compositions
And, splitting amlodipine or its salt into levamlodipine salt increases the production process, and in the process of splitting, there is loss of dexamlodipine or its salt and the introduction of impurities, which greatly increases the cost of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amlodipine and fosinopril sodium medical composition and preparation method thereof
  • Amlodipine and fosinopril sodium medical composition and preparation method thereof
  • Amlodipine and fosinopril sodium medical composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Add 9g of amlodipine maleate, 21ml of ethanol, 42ml of dimethyl sulfoxide, and 7ml of deionized water into a 100ml reaction kettle, adjust the pH to 6 with triethylamine or acetic acid, stir for 30min, seal it, and place it in an oven at 125°C After 3 days, take out the reaction kettle, place the reaction kettle in a 40KHz ultrasonic field to cool down naturally, wait for the reaction kettle to cool down slowly to 70°C, open the reaction kettle, add 70°C deionized water dropwise, white crystalline powder precipitates, and cool to room temperature And turn off the ultrasonic wave, filter, wash with dichloromethane and ethanol, and dry in vacuum for 2 hours to obtain amlodipine maleate hydrate crystals. The particle size range of the crystal is 75-150 μm, mp: 178-180°C.

[0049] Adopt U.S. Perkin-Elmer company PE 2400II elemental analyzer, elemental analysis (%) calculated value is: C (52.22), H (5.84), Cl (6.42), N (5.08), O (30.44); Elemental analysis (%) ) found: C (5...

Embodiment 2

[0053] Add 9g of amlodipine maleate, 21ml of ethanol, 42ml of dimethyl sulfoxide, and 7ml of deionized water into a 100ml reaction kettle, adjust the pH to 6.5 with triethylamine or acetic acid, stir for 30min, seal it, and place it in an oven at 130°C After 3 days, the reactor was taken out, and the reactor was placed in a 40KHz ultrasonic field to cool down naturally. After the reactor was slowly cooled to 75°C, the reactor was opened, and deionized water at 75°C was added dropwise. White crystalline powder precipitated, and cooled to room temperature. And turn off the ultrasonic wave, filter, wash with dichloromethane and ethanol, and dry in vacuum for 3 hours to obtain amlodipine maleate hydrate crystals. The particle size range of the crystal is 75-150 μm, mp: 178-180°C.

[0054] Adopt U.S. Perkin-Elmer company PE 2400II elemental analyzer, elemental analysis (%) calculated value is: C (52.22), H (5.84), Cl (6.42), N (5.08), O (30.44); Elemental analysis (%) ) found: C (...

Embodiment 3

[0058] Ingredients as follows:

[0059]

[0060] 1000 pieces are made

[0061] Preparation:

[0062] Raw and auxiliary materials were respectively crushed through 80-mesh sieve, microcrystalline cellulose and amlodipine maleate hydrate crystals were mixed, and then mixed with fosinopril sodium, compressible starch and low-substituted hydroxypropyl cellulose, cross-linked The polyvinylpyrrolidone is mixed evenly, and then mixed with magnesium stearate for 5 minutes, the intermediate is tested, and the composition chip is obtained by direct tableting.

[0063] Finally, the prescribed amount of magnesium stearate and essence are added, mixed evenly, and after the intermediate is qualified, the medicinal composition chip is obtained by direct tableting; and the film coating is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to an amlodipine and fosinopril sodium medical composition, which comprises the following components in parts by weight: 5 to 10 parts of amlodipine, 10 to 40 parts of fosinopril sodium, 5 to 50 parts of compressible starch, 10 to 60 parts of microcrystalline cellulose, 15 to 40 parts of low-substitution hydroxy propyl cellulose, 10 to 45 parts of crospolyvinylpyrrolidone, and 1 to 3 parts of magnesium stearate, wherein the amlodipine is a maleic amlodipine hydrate crystal, and the molecular formula of the maleic amlodipine hydrate crystal is C24H29ClN2O9.1.5H2O. The medical composition has stable and quick action, stable and durable effect and high bioavailability.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a medicinal composition of amlodipine and fosinopril sodium and a preparation method thereof. Background technique [0002] Fosinopril, Chinese alias: 4-cyclohexyl-1-[[[2-methyl-1-(1-propionyloxy)propoxy](4-phenylbutyl)phosphinyl]acetyl] -L-proline, English name: Fosinopril, molecular formula: C 30 h 46 NO 7 P, molecular weight: 563.66. Fosinopril is a new phosphorus-containing angiotensin-converting enzyme inhibitor (ACEI) drug that was launched in China in 2007. As a prodrug, it has a weak direct inhibitory effect on ACE, but it is slowly and incompletely absorbed after oral administration, and is rapidly transformed into the more active diacid metabolite fosinoprilat. Fosinoprilat inhibits ACE activity through the combination of secondary phosphate groups and zinc ions in the active site of ACE. The inhibitory effect of this drug on ACE produces the followin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/675A61K31/4422A61K9/28A61P9/10A61P9/12
Inventor 马鹰军王小树钟正明罗韬
Owner HAINAN JINRUI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products